Internal Medicine, Rheumatology · Scranton, PA
NPI
1275519530
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
501 Madison Ave
Scranton, PA, 18510
Phone (570) 343-2383
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
136,746 services
Medicare patients, 2024
992
Average age 72
Drug cost, 2024
$1.3M
4,906 prescriptions
Company payments, 2025
$27K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julio A Ramos was code J1602 (injection, golimumab, 1 mg, for intravenous use), 46,400 times for 52 patients. In total Julio A Ramos billed 136,746 services in 62 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-08-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 46,400 | 52 | $9.04 | $419K |
| J0897 Injection, denosumab, 1 mg | Office | 14,581 | 139 | $20.52 | $299K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 14,280 | 14 | $8.61 | $123K |
| J9312 Injection, rituximab, 10 mg | Office | 3,900 | 16 | $61.31 | $239K |
| 99214 Office E&M - Established | Office | 1,800 | 799 | $91.32 | $164K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,248 | 13 | $0.10 | $127 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,018 | 555 | $12.69 | $13K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 802 | 254 | $36.94 | $30K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 782 | 113 | $0.71 | $557 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 772 | 330 | $48.67 | $38K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 535 | 94 | $0.52 | $277 |
| 96413 Chemotherapy Administration | Office | 519 | 92 | $101.89 | $53K |
| 96401 Chemotherapy Administration | Office | 389 | 152 | $56.56 | $22K |
| 99497 Care Management/Coordination | Office | 228 | 227 | $52.76 | $12K |
| 96415 Chemotherapy Administration | Office | 183 | 26 | $22.07 | $4,039 |
By year: 2022 $1.7M for 91,970 services; 2023 $2.2M for 128,130 services; 2024 $2.1M for 136,746 services.
Medicare prescription drug claims, 2024
In 2024, the drug Julio A Ramos prescribed most often to Medicare patients was Duloxetine Hcl, with 606 prescriptions and refills. In total Julio A Ramos wrote 4,906 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Duloxetine Hcl Generic | 606 | 1,183 | 180 | $17K |
| Gabapentin Generic | 333 | 644 | 113 | $4,942 |
| Hydroxychloroquine Sulfate Generic | 323 | 719 | 104 | $15K |
| Celecoxib Generic | 293 | 339 | 109 | $6,606 |
| Prednisone Generic | 271 | 382 | 125 | $1,696 |
| Meloxicam Generic | 269 | 350 | 88 | $1,218 |
| Methotrexate Methotrexate Sodium | 212 | 487 | 71 | $4,674 |
| Pregabalin Generic | 175 | 201 | 52 | $2,573 |
| Leflunomide Generic | 174 | 340 | 57 | $9,031 |
| Baclofen Generic | 133 | 162 | 69 | $1,827 |
| Topiramate Generic | 121 | 231 | 28 | $2,289 |
| Tizanidine Hcl Generic | 100 | 154 | 41 | $2,196 |
| Oxcarbazepine Generic | 79 | 117 | 24 | $1,804 |
| Doxycycline Hyclate Generic | 72 | 172 | 27 | $2,352 |
| Allopurinol Generic | 68 | 157 | 22 | $755 |
Brand drugs: 289 claims; generic drugs: 4,606 claims; opioid claims: 307.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Julio A Ramos $27K ($27K in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $26K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 74 | $26K |
| Amgen Inc. AMGN | 16 | $313 |
| GlaxoSmithKline, LLC. GSK | 7 | $296 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $228 |
| UCB, Inc. UCB.BR | 8 | $163 |
| Janssen Biotech, Inc. JNJ | 3 | $147 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $81.41 |
| Organon LLC OGN | 2 | $56.16 |
| Genentech USA, Inc. ROG.SW | 2 | $42.02 |
| Pfizer Inc. PFE | 2 | $37.45 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.